Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Andrew P DeFillipis Added: 2 years ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were… View more
Author(s): Mikhail Kosiborod Added: 2 years ago
ACC.24 — We are joined onsite by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF DM Trial (NCT04916470).The STEP HFpEF DM study aimed to investigate the effect of taking semaglutide 2.4mg once weekly in patients with heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus type 2. The study looked at the impact of… View more
Author(s): Milton Packer Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core… View more
Author(s): Javed Butler Added: 1 year ago
Professor Javed Butler presents a routine case study of a HFrEF patient recently discharged from hospital for decompensated heart failure. The patient was treated with IV diuretics but now requires optimization of his on-going therapy, Professor Butler asks, ‘what should we do first?’.Follow the following links to watch further case studies on Worsening Heart Failure presented by Gianluigi… View more
Author(s): John JV McMurray Added: 1 year ago
EASD 24 - We are joined by Professor John McMurray (University of Glasgow, UK) to discuss the key findings from a diabetes subgroup analysis of the FINEARTS-HF study.Interview Questions:1. What is the reasoning behind this analysis?2. What was the study design and patient cohort?3. What are the key findings?4. In your opinion, what can explain this risk reduction?5. What are the take-home… View more
Author(s): Michelle Kittleson Added: 1 year ago
ESC 2024 - We are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) for a concise and insightful summary of the hot-line and late-breaking data that is expected to have an impact on heart failure care.Trials covered in detail include:FINEARTS HFHELIOS-BRESHAPE HF2Recorded remotely from Los Angeles, 2024.Editors: Jordan Rance and Mirjam Boros.Videographers: Mike Knight, Dan Brent,… View more
Author(s): Mirvat Alasnag , Khaled Al-Shaibi Added: 7 months ago
ESC Congress 2025 – The second day of ESC Congress 2025 brought forth significant findings with major implications for cardiovascular care.Interventional specialists Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) share their expert analysis of the essential insights from the day's hot line trial presentations.Day 2 Highlights:MAPLE-HCMODYSSEY-HCMBETAMI… View more
Author(s): Harriette Van Spall , Tauben Averbuch Added: 1 year ago
HFA 2024 — Dr Tauben Averbuch and Dr Harriette Van Spall (McMaster University, Hamilton, CA) discuss the findings from the PACT-HF trial. In this analysis of PACT-HF, investigators looked at long term sex-specific clinical outcomes and healthcare resource utilisation following hospitalisation for heart failure at 5 years.Findings shows that clinical outcomes and overall costs were similar between… View more
Author(s): Vijay Chopra Added: 10 months ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps… View more
Author(s): Ambarish Pandey Added: 1 year ago
HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).Interview Questions:What is the reasoning behind this study?Could you tell us about the mechanism… View more